EPIVIR (KAISER FOUNDATION HOSPITALS)
Welcome to the PulseAid listing for the EPIVIR drug offered from KAISER FOUNDATION HOSPITALS. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | KAISER FOUNDATION HOSPITALS |
NON-PROPRIETARY NAME: | lamivudine |
SUBSTANCE NAME: | LAMIVUDINE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, FILM COATED |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2011-03-15 |
END MARKETING DATE: | 0000-00-00 |
EPIVIR HUMAN PRESCRIPTION DRUG Details:
Item Description | EPIVIR from KAISER FOUNDATION HOSPITALS |
LABELER NAME: | KAISER FOUNDATION HOSPITALS |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 150(mg/1) |
START MARKETING DATE: | 2011-03-15 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0179-0087_625b618a-b57c-45cc-9052-de0586e1997f |
PRODUCT NDC: | 0179-0087 |
APPLICATION NUMBER: | NDA020564 |
Other LAMIVUDINE Pharmaceutical Manufacturers / Labelers: